1.1.3 Immunosuppressants
Mirikizumab (Omvoh®) |
This High-Cost Drug has been approved for the following indications: - for treating moderately to severely active ulcerative colitis in adults as per NICE TA925. |
For more information and NICE Guidance Click Here | Mirikizumab for treating moderately to severely active ulcerative colitis NICE TA925 ICB commissioned - approval via Blueteq |
|
This High-Cost Drug has been approved for the following indications: - Ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults only if: when conventional or biological treatments cannot be tolerated or are not working well enough, and infliximab is not suitable, and the company provides it according to the commercial arrangement. |
For more information and NICE Guidance Click Here | Ozanimod for treating moderately to severely active ulcerative colitis NICE TA828 ICB commissioned - approval via Blueteq |
Risankizumab - SKYRIZI® | This High-Cost Drug has been approved for the following indications: - Treatment of previously treated moderately to severely active Crohn’s disease |
For more information and NICE Guidance Click Here |
Risankizumab for previously treated moderately to severely active Crohn's disease NICE Guidance TA888 |
Upadacitinib | This High-Cost Drug has been approved for the following indications: - Treatment of moderately to severely active ulcerative colitis in adults: when conventional or biological treatment cannot be tolerated, or if the condition has not responded well enough or has stopped responding to these treatments as per NICE Guidance |
For more information and NICE Guidance Click Here | Upadacitinib for treating moderately to severely active ulcerative colitis NICE Guidance TA856 |
Upadacitinib | This High-Cost Drug has been approved for the following indications: - Treatment of previously treated moderately to severely active Crohn’s disease |
For more information and NICE Guidance Click Here | Upadacitinib for previously treated moderately to severely active Crohn’s disease NICE Guidance TA905 |
- First Line Choice
- On Formulary
- Specialist Initiation Only
- Hospital Only
- KMPT Initiation Only